{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:53:59Z","timestamp":1777859639514,"version":"3.51.4"},"reference-count":13,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T00:00:00Z","timestamp":1513209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction and Objective:<\/jats:title>\n                    <jats:p>Postmarketing reports and warnings of serious adverse events such as diabetic ketoacidosis (DKA) have raised concern regarding the safety of sodium\u2013glucose cotransporter 2 inhibitors (SGLT2i). This report describes 2 cases of symptomatic SGLT2i-associated euglycemic DKA (euDKA) leading to hospitalization in patients with type 2 diabetes mellitus (DM) previously well controlled on oral medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Reports:<\/jats:title>\n                    <jats:p>Subject 1 is a 55-year-old female admitted with euDKA precipitated by infection and managed with intravenous insulin. This case was notable for a delayed diagnosis of euDKA and lack of clinical improvement despite withholding dapagliflozin. Subject 2 is a 62-year-old male admitted with euDKA precipitated by infection. His clinical condition improved rapidly and euDKA responded to withdrawal of empagliflozin alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>Applying the Naranjo adverse medication reaction probability scale to each case (subject 1 score = 3 points; subject 2 score = 4 points) suggests these are possible adverse reactions to SGLT2i. Data from randomized controlled trials suggest DKA events in adults with type 2 DM receiving SGLT2i are rare and similar to placebo. However, data from a large cohort suggest these events occur more frequently and are associated with a 2-fold increased risk of DKA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This class of medications may be associated with a higher real-world risk of DKA in adults with type 2 DM than previously reported. Patients prescribed these medications should receive vigilant assessment for features of traditional DKA as well as euDKA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0897190017748049","type":"journal-article","created":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T01:44:49Z","timestamp":1513388689000},"page":"240-243","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Euglycemic Diabetic Ketoacidosis Associated With Sodium\u2013Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy"],"prefix":"10.1177","volume":"32","author":[{"given":"Ryan B.","family":"Dull","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Creighton University School of Pharmacy and Health Professions, Omaha, NE, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikayla L.","family":"Spangler","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Creighton University School of Pharmacy and Health Professions, Omaha, NE, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily L.","family":"Knezevich","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Creighton University School of Pharmacy and Health Professions, Omaha, NE, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britney M.","family":"Lau","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Creighton University School of Pharmacy and Health Professions, Omaha, NE, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,12,14]]},"reference":[{"key":"bibr1-0897190017748049","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12401"},{"key":"bibr2-0897190017748049","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors may result in a serious condition of too much acid in the blood. Bethesda, MD: US Food and Drug Administration; 2015. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm446845.htm. Accessed May 30, 2017."},{"key":"bibr3-0897190017748049","doi-asserted-by":"publisher","DOI":"10.4158\/EP161292.PS"},{"key":"bibr4-0897190017748049","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1884"},{"key":"bibr5-0897190017748049","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1881"},{"key":"bibr6-0897190017748049","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr7-0897190017748049","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0843"},{"key":"bibr8-0897190017748049","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"bibr9-0897190017748049","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0542"},{"key":"bibr10-0897190017748049","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.11.002"},{"key":"bibr11-0897190017748049","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1251"},{"key":"bibr12-0897190017748049","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1701990"},{"key":"bibr13-0897190017748049","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190017748049","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190017748049","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190017748049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:34:49Z","timestamp":1777509289000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190017748049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,14]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1177\/0897190017748049"],"URL":"https:\/\/doi.org\/10.1177\/0897190017748049","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,14]]}}}